Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency
- PMID: 8408618
- PMCID: PMC288323
- DOI: 10.1172/JCI116750
Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency
Abstract
Deficiency of the cholesteryl ester transfer protein (CETP) in humans is characterized by markedly elevated plasma concentrations of HDL cholesterol and apoA-I. To assess the metabolism of HDL apolipoproteins in CETP deficiency, in vivo apolipoprotein kinetic studies were performed using endogenous and exogenous labeling techniques in two unrelated homozygotes with CETP deficiency, one heterozygote, and four control subjects. All study subjects were administered 13C6-labeled phenylalanine by primed constant infusion for up to 16 h. The fractional synthetic rates (FSRs) of apoA-I in two homozygotes with CETP deficiency (0.135, 0.134/d) were found to be significantly lower than those in controls (0.196 +/- 0.041/d, P < 0.01). Delayed apoA-I catabolism was confirmed by an exogenous radiotracer study in one CETP-deficient homozygote, in whom the fractional catabolic rate of 125I-apoA-I was 0.139/d (normal 0.216 +/- 0.018/d). The FSRs of apoA-II were also significantly lower in the homozygous CETP-deficient subjects (0.104, 0.112/d) than in the controls (0.170 +/- 0.023/d, P < 0.01). The production rates of apoA-I and apoA-II were normal in both homozygous CETP-deficient subjects. The turnover of apoA-I and apoA-II was substantially slower in both HDL2 and HDL3 in the CETP-deficient homozygotes than in controls. The kinetics of apoA-I and apoA-II in the CETP-deficient heterozygote were not different from those in controls. These data establish that homozygous CETP deficiency causes markedly delayed catabolism of apoA-I and apoA-II without affecting the production rates of these apolipoproteins.
Similar articles
-
Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.J Clin Invest. 1995 Sep;96(3):1573-81. doi: 10.1172/JCI118196. J Clin Invest. 1995. PMID: 7657828 Free PMC article.
-
Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein.J Clin Invest. 1993 Aug;92(2):1009-17. doi: 10.1172/JCI116606. J Clin Invest. 1993. PMID: 8349786 Free PMC article.
-
Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.N Engl J Med. 1990 Nov 1;323(18):1234-8. doi: 10.1056/NEJM199011013231803. N Engl J Med. 1990. PMID: 2215607
-
Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies.J Intern Med. 1995 Jan;237(1):5-12. doi: 10.1111/j.1365-2796.1995.tb01133.x. J Intern Med. 1995. PMID: 7830031 Review.
-
Metabolic and genetic control of HDL cholesterol levels.J Intern Med. 1992 Jun;231(6):661-8. doi: 10.1111/j.1365-2796.1992.tb01255.x. J Intern Med. 1992. PMID: 1619389 Review.
Cited by
-
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.J Lipid Res. 2009 Jul;50(7):1456-62. doi: 10.1194/jlr.P800037-JLR200. Epub 2009 Feb 3. J Lipid Res. 2009. PMID: 19193611 Free PMC article. Clinical Trial.
-
Interaction between cholesteryl ester transfer protein and hepatic lipase encoding genes and the risk of type 2 diabetes: results from the Telde study.PLoS One. 2011;6(11):e27208. doi: 10.1371/journal.pone.0027208. Epub 2011 Nov 3. PLoS One. 2011. PMID: 22073289 Free PMC article.
-
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.Arterioscler Thromb Vasc Biol. 2016 May;36(5):994-1002. doi: 10.1161/ATVBAHA.115.306680. Epub 2016 Mar 10. Arterioscler Thromb Vasc Biol. 2016. PMID: 26966279 Free PMC article. Clinical Trial.
-
Glycosylation of HDL-Associated Proteins and Its Implications in Cardiovascular Disease Diagnosis, Metabolism and Function.Front Cardiovasc Med. 2022 May 27;9:928566. doi: 10.3389/fcvm.2022.928566. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35694676 Free PMC article. Review.
-
Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner.J Clin Invest. 1996 Apr 15;97(8):1844-51. doi: 10.1172/JCI118614. J Clin Invest. 1996. PMID: 8621767 Free PMC article.